Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | BCL2 | P10415 | 5/20 | 0.52 |
| ▸ | MCL1 | Q07820 | 5/20 | 0.52 |
| ▸ | HTR7 | P34969 | 1/20 | 0.49 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.49 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3927600 | 1.00 | MEN1 (0.53) | MEN1NPC1RAB9AKMT2ABCL2 | |
| SCHEMBL21245274 | 0.88 | BCL2 (0.50) | MEN1NPC1RAB9AKMT2ABCL2 | |
| SCHEMBL14274532 | 0.85 | MEN1 (0.52) | MEN1NPC1RAB9AKMT2ABCL2 | |
| SCHEMBL860936 | 0.84 | MCL1 (0.54) | MEN1NPC1RAB9AKMT2ABCL2 | |
| SCHEMBL17602263 | 0.83 | MEN1 (0.56) | MEN1NPC1RAB9AKMT2ABCL2 | |
| SCHEMBL21245229 | 0.83 | BCL2 (0.48) | MEN1NPC1RAB9AKMT2ABCL2 | |
| SCHEMBL4191518 | 0.82 | MEN1 (0.54) | MEN1NPC1RAB9AKMT2ABCL2 | |
| SCHEMBL25631028 | 0.82 | SCN9A (0.55) | MEN1NPC1RAB9AKMT2ABCL2 | |
| SCHEMBL27587634 | 0.82 | BCL2 (0.56) | BCL2MCL1SRD5A2 | |
| SCHEMBL4394621 | 0.82 | MTNR1A (0.56) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7129250-B2 | Neuroprotective and anti-proliferative compounds | AEGERA THERAPEUTICS INC. (CA) | 2006-10-31 | — | — | US | disclosed |
| US-20040220202-A1 | Neuroprotective and anti-proliferative compounds | AEGERA THERAPEUTICS INC. (CA) | 2004-11-04 | — | — | US | disclosed |
| US-20040102467-A1 | Neuroprotective and anti-proliferative compounds | AEGERA THERAPEUTICS INC. (CA) | 2004-05-27 | — | — | US | disclosed |
| EP-1283836-A2 | NEUROPROTECTIVE AND ANTI-PROLIFERATIVE COMPOUNDS | Aegera Therapeutics Inc. (CA) | 2003-02-19 | — | — | EP | disclosed |
| WO-2001087887-A2 | NEUROPROTECTIVE AND ANTI-PROLIFERATIVE COMPOUNDS | AEGERA THERAPEUTICS INC. (CA) | 2001-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220202-A1 | Neuroprotective and anti-proliferative compounds | NLN, MKI67, BDNF | MEN1 3197/4885NPC1 2617/4885RAB9A 3387/4885 |
| US-20040102467-A1 | Neuroprotective and anti-proliferative compounds | MKI67, NLN, BDNF | MEN1 3337/4885NPC1 2589/4885RAB9A 3429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.